Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review

Overview of attention for article published in Frontiers in oncology, August 2024

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 21,392 followers.

RT @EGFRResisters: Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSC…

RT @EGFRResisters: Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSC…

RT @EGFRResisters: Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSC…

RT @EGFRResisters: Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSC…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.